Added to YB: 2024-01-22
Pitch date: 2024-01-19
ORTX [bullish]
Orchard Therapeutics plc
+0.6%
current return
Author Info
No bio for this author
Company Info
Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany.
Market Cap
$380.1M
Pitch Price
$16.60
Price Target
16.85 (+1%)
Dividend
N/A
EV/EBITDA
-3.25
P/E
-3.94
EV/Sales
13.85
Sector
Biotechnology
Category
special_situation
Orchard Therapeutics: Still An Attractive Merger Arbitrage Opportunity With A CVR
$ORTX: Kyowa Kirin to acquire for $16/share+$1 CVR on OTL-200 FDA nod by 2024 end. High approval odds given EMA ok & FDA waiver. $0.44 premium on CVR=$93% return if approved by 3/18/24. Binary outcome but strong signs of success. Shares delist 1/24. Attractive FDA bet.
Read full article (3 min)